Private equity firm Blackstone is set to sell Japanese drugmaker Alinamin Pharmaceutical to North Asian buyout fund MBK Partners for 350 billion yen ($2.17 billion), according to the Nikkei newspaper. Blackstone acquired Alinamin in 2021 and the company subsequently expanded its overseas sales by establishing a unit in Taiwan. MBK Partners plans to leverage its expertise in consumer goods acquisitions to enhance the value of Alinamin. Neither MBK, Blackstone, nor Alinamin have commented on the report. [28055aed]